trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. inclusion conjunctivitis caused by chlamydia trachomatis. uncomplicated urethral, endocervical or rectal infections in adults caused by chlamydia trachomatis. nongonococcal urethritis caused by ureaplasma urealyticum. relapsing fever due to borrelia recurrentis. doxycycline capsules, usp are also indicated for the treatment of infections caused by the following gram-negative microorganisms: chancroid caused by haemophilus ducreyi. plague due to yersinia pestis. tularemia due to francisella tularensis. cholera caused by vibrio cholerae. campylobacter fetus infections caused by campylobacter fetus. brucellosis due to brucella species (in conjunction with streptomycin). bartonellosis due to bartonella bacilliformis. granuloma inguinale caused by klebsiella granulomatis. because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. doxycycline capsules, usp are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: escherichia coli enterobacter aerogenes shigella species acinetobacter species respiratory tract infections caused by haemophilus influenzae. respiratory tract and urinary tract infections caused by klebsiella species. doxycycline capsules, usp are indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: upper respiratory infections caused by streptococcus pneumoniae. anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: uncomplicated gonorrhea caused by neisseria gonorrhoeae. syphilis caused by treponema pallidum. yaws caused by treponema pallidum subspecies pertenue. listeriosis due to listeria monocytogenes. vincent's infection caused by fusobacterium fusiforme. actinomycosis caused by actinomyces israelii. infections caused by clostridium species. in acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. in severe acne, doxycycline may be useful adjunctive therapy.

fficile. c. difficile produces toxins a and b which contribute to the development of cdad. hypertoxin producing strains of c. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. cdad must be considered in all patients who present with diarrhea following antibiotic use. careful medical history is necessary since cdad has been reported to occur over two months after the administration of antibacterial agents. if cdad is suspected or confirmed, ongoing antibiotic use not directed against c. difficile may need to be discontinued. appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of c. difficile, and surgical evaluation should be instituted as clinically indicated. intracranial hypertension (ih, pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline capsules. clinical manifestations of ih include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. women of childbearing age who are overweight or have a history of ih are at greater risk for developing tetracycline associated ih. concomitant use of isotretinoin and doxycycline capsules should be avoided because isotretinoin is also known to cause pseudotumor cerebri. although ih typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. if visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize. all tetracyclines form a stable calcium complex in any bone-forming tissue. a decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. this reaction was shown to be reversible when the drug was discontinued. results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). evidence of embryo toxicity has been noted in animals treated early in pregnancy. if any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus. the antianabolic action of the tetracyclines may cause an increase in bun. studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function. photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

s severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). for pediatric patients weighing over 45 kg, the usual adult dose should be used. the therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage. when used in streptococcal infections, therapy should be continued for 10 days. administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (see adverse reactions) if gastric irritation occurs, it is recommended that doxycycline be given with food or milk. the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment. uncomplicated gonococcal infections in adults (except anorectal infections in men) 100 mg, by mouth, twice a day for 7 days. as an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. acute epididymo-orchitis caused by n. gonorrhoeae 100 mg, by mouth, twice a day for at least 10 days. primary and secondary syphilis 300 mg a day in divided doses for at least 10 days. uncomplicated urethral, endocervical, or rectal infection in adults caused by chlamydia trachomatis 100 mg, by mouth, twice a day for at least 7 days. nongonococcal urethritis caused by c. trachomatis and u. urealyticum: 100 mg, by mouth, twice a day for at least 7 days. acute epididymo-orchitis caused by c. trachomatis 100 mg, by mouth, twice a day for at least 10 days. inhalational anthrax (post-exposure) adults: 100 mg of doxycycline, by mouth, twice a day for 60 days. children: weighing less than 45 kg 2.2 mg/kg of body weight, by mouth, twice a day for 60 days. children weighing 45 kg or more should receive the adult dose.

eported but is uncommon. photosensitivity is discussed above. (see warnings.) renal toxicity rise in bun has been reported and is apparently dose related. (see warnings.) hypersensitivity reactions urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus. blood hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines. other intracranial hypertension (ih, pseudotumor cerebri) has been associated with the use of tetracyclines. (see precautions-general.) when given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. no abnormalities of thyroid function are known to occur.

renal insufficiency (creatinine clearance below 10 ml/min). studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. hemodialysis does not alter serum half-life. population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients (2 years to 18 years of age) showed that allometrically–scaled clearance (cl) of doxycycline in pediatric patients ≥2 years to ≤8 years of age (median [range] 3.58 [2.27 to 1 0.82] l/h/70 kg, n =11) did not differ significantly from pediatric patients >8 to 18 years of age (3.27 [1.11 to 8.12] l/h/70 kg, n=33). for pediatric patients weighing ≤45 kg, body weight normalized doxycycline cl in those ≥2 years to ≤8 years of age (median [range] 0.071 [0 .041 to 0.202] l/kg/h, n=10) did not differ significantly from those >8 years to 18 years of age (0.081 [0.035 to 0.126] l/kg/h, n=8). in pediatric patients weighing >45 kg, no clinically significant differences in body weight normalized doxycycline cl were observed between those ≥2 years to ≤8 years (0.050 l/kg/h, n=1) and those >8 years to 18 years of age (0.044 [0.014 to 0.121] l/kg/h, n=25). no clinically significant difference in cl between oral and iv dosing was observed in the small cohort of pediatric patients who received the oral (n=19) or iv (n=21) formulation alone. microbiology mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. doxycycline has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. resistance cross resistance with other tetracyclines is common. antimicrobial activity doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections (see indications and usage). gramnegative bacteria acinetobacter species bartonella bacilliformis brucella species campylobacter fetus enterobacter aerogenes escherichia coli francisella tularensis haemophilus ducreyi haemophilus influenzae klebsiella granulomatis klebsiella species neisseria gonorrhoeae shigella species vibrio cholerae yersinia pestis grampositive bacteria bacillus anthracis listeria monocytogenes streptococcus pneumoniae anaerobic bacteria clostridium species fusobacterium fusiforme propionibacterium acnes other bacteria nocardiae and other actinomyces species borrelia recurrentis chlamydophila psittaci chlamydia trachomatis mycoplasma pneumoniae rickettsiae treponema pallidum treponema pallidum subspecies pertenue ureaplasma urealyticum parasites balantidium coli entamoeba species susceptibility testing methods for specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by fda for this drug, please see: https://www.fda.gov/stic.

68382-706-10 in bottle of 1000 capsules ndc 68382-706-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose capsules doxycycline capsules usp, 100 mg are light yellow to yellow powder filled in hard gelatin capsule shells having an opaque yellow cap and an opaque orange body printed with 707 on cap in black ink and are supplied as follows: ndc 68382-707-06 in bottle of 30 capsules ndc 68382-707-18 in bottle of 50 capsules ndc 68382-707-16 in bottle of 90 capsules ndc 68382-707-01 in bottle of 100 capsules ndc 68382-707-21 in bottle of 250 capsules ndc 68382-707-05 in bottle of 500 capsules ndc 68382-707-10 in bottle of 1000 capsules ndc 68382-707-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose capsules storage store at 20° to 25°c (68° to 77°f). [see usp controlled room temperature]. dispense in a tight, light-resistant container as defined in the usp. animal pharmacology and animal toxicology hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline po4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline po4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline. minocycline, tetracycline po4, methacycline, doxycycline, tetracycline base, oxytetracycline hcl and tetracycline hcl were goitrogenic in rats fed a low iodine diet. this goitrogenic effect was accompanied by high radioactive iodine uptake. administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet. treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.